Drug Profile


Alternative Names: Drondarone; Multaq; SB-33589; SR 33589; SR 33589B

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Benzofurans; Class III antiarrhythmics; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Calcium channel antagonists; Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atrial fibrillation; Atrial flutter

Most Recent Events

  • 11 Jul 2011 European Medicines Agency broadens ongoing benefit-risk assessment of dronedarone to include review of cardiovascular risk
  • 07 Jul 2011 sanofi-aventis terminates the phase III PALLAS trial in permanent Atrial fibrillation worldwide (NCT01151137)
  • 06 May 2011 sanofi-aventis completes a phase II trial in Atrial fibrillation in Japan (NCT01213368)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top